Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs

Author(s): Francesca Maira, Alessia Catania, Saverio Candido, Alessia Erika Russo, James A. McCubrey, Massimo Libra, Grazia Malaponte, Concettina Fenga

Journal Name: Current Drug Delivery

Volume 9 , Issue 1 , 2012

Become EABM
Become Reviewer
Call for Editor


Cutaneous melanoma is the most aggressive skin cancer. Beside surgery, it is treated with chemotherapy and immunotherapy. However, many patients relapse after adjuvant therapy. The recent identification of several key molecular pathways implicated in the pathogenesis of melanoma is spreading development of a number of new translational targeted therapies which could play an important role in overcoming or minimizing resistance to chemotherapeutic drugs and proapoptotic therapies. This review summarizes environmental factors and the most significant molecular events involved in melanoma pathogenesis, disclosing mechanisms responsible for drug resistance and pointing out the clinical view for emerging targeted therapies. Standard therapies and an update on the current clinical trials are also described.

Keywords: Drug resistance, melanoma, BRAF, PI3K/AKT/mTOR, AF/MEK/ERK, sensitivity, targeted therapy, MEK, ERK, gene mutations

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [17 - 29]
Pages: 13
DOI: 10.2174/156720112798376032

Article Metrics

PDF: 28